From: Altered monocyte activation markers in Tourette’s syndrome: a case–control study
Variable | Group | Mean ± SD | Rank sum | z-value | p-value* |
---|---|---|---|---|---|
Monocytes/nl | Patients | 0.57 ± 0.22 | 50.1 | −2.152 | 0.031 |
Controls | 0.47 ± 0.11 | 38.37 | |||
TNF-alpha pg/ml | Patients | 0.43 ± 0.18 | 33.09 | −2.421 | 0.015 |
Controls | 0.56 ± 0.25 | 45.39 | |||
IL-6 pg/ml | Patients | 1.89 ± 1.71 | 39.41 | −1.215 | n.s. |
Controls | 1,74 ± 1,64 | 33.43 | |||
IL1-ra ng/ml | Patients | 0.03 ± 0.09 | 36.11 | −2.813 | 0.005 |
Controls | 0.04 ± 0.06 | 51.24 | |||
sCD14 ng/ml | Patients | 6.37 ± 1.43 | 30.25 | −4.934 | <0.0001 |
Controls | 8.40 ± 2.00 | 56,68 | |||
CRP mg/dl | Patients | 0.43 ± 0.27 | 45.53 | −2.013 | 0.044 |
Controls | 0.37 ± 0.37 | 37.85 | |||
Neopterin nmol/l | Patients | 6.03 ± 2.19 | 48.51 | −2.084 | 0.037 |
Controls | 5.19 ± 1.84 | 37.36 |